Equities analysts expect that ChemoCentryx Inc (NASDAQ:CCXI) will post earnings per share of ($0.28) for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for ChemoCentryx’s earnings, with estimates ranging from ($0.39) to $0.03. ChemoCentryx reported earnings of ($0.22) per share during the same quarter last year, which indicates a negative year over year growth rate of 27.3%. The business is expected to announce its next quarterly earnings results on Monday, November 2nd.
On average, analysts expect that ChemoCentryx will report full year earnings of ($0.69) per share for the current financial year, with EPS estimates ranging from ($0.79) to ($0.34). For the next year, analysts anticipate that the business will post earnings of ($1.44) per share, with EPS estimates ranging from ($2.15) to ($1.02). Zacks’ EPS calculations are an average based on a survey of research firms that cover ChemoCentryx.
ChemoCentryx (NASDAQ:CCXI) last announced its earnings results on Monday, August 10th. The biopharmaceutical company reported $0.29 EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.63. The company had revenue of $49.44 million during the quarter, compared to analysts’ expectations of $8.31 million. ChemoCentryx had a negative return on equity of 19.57% and a negative net margin of 39.19%.
A number of brokerages recently commented on CCXI. HC Wainwright restated a “buy” rating and issued a $69.00 price objective on shares of ChemoCentryx in a research report on Monday, May 18th. Raymond James raised their price target on ChemoCentryx from $95.00 to $100.00 and gave the company a “strong-buy” rating in a report on Tuesday, August 11th. ValuEngine downgraded ChemoCentryx from a “buy” rating to a “hold” rating in a research note on Thursday, July 2nd. Canaccord Genuity reiterated a “buy” rating on shares of ChemoCentryx in a research report on Wednesday, June 3rd. Finally, Piper Sandler raised their target price on ChemoCentryx from $54.00 to $70.00 and gave the company an “overweight” rating in a report on Monday, May 18th. Three analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $69.50.
We’re just getting word of this; an all new way to trade – before the bell rings on Wall Street – allowing traders to achieve up to 1,139% return.
In other news, CEO Thomas J. Schall sold 88,753 shares of the stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $65.08, for a total value of $5,776,045.24. Following the sale, the chief executive officer now directly owns 2,357,310 shares in the company, valued at $153,413,734.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder (International) Ltd Vifor sold 133,074 shares of the firm’s stock in a transaction that occurred on Friday, July 24th. The stock was sold at an average price of $54.62, for a total transaction of $7,268,501.88. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,289,599 shares of company stock valued at $75,130,117. Company insiders own 9.30% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the business. Ameritas Investment Partners Inc. grew its stake in shares of ChemoCentryx by 7.4% in the second quarter. Ameritas Investment Partners Inc. now owns 3,929 shares of the biopharmaceutical company’s stock worth $226,000 after purchasing an additional 270 shares in the last quarter. Arizona State Retirement System boosted its holdings in shares of ChemoCentryx by 3.5% during the second quarter. Arizona State Retirement System now owns 9,206 shares of the biopharmaceutical company’s stock worth $530,000 after acquiring an additional 314 shares during the period. JPMorgan Chase & Co. grew its position in shares of ChemoCentryx by 2.5% in the first quarter. JPMorgan Chase & Co. now owns 13,435 shares of the biopharmaceutical company’s stock valued at $540,000 after purchasing an additional 330 shares during the last quarter. Principal Financial Group Inc. increased its stake in shares of ChemoCentryx by 3.4% during the first quarter. Principal Financial Group Inc. now owns 14,223 shares of the biopharmaceutical company’s stock worth $571,000 after purchasing an additional 468 shares during the period. Finally, Los Angeles Capital Management & Equity Research Inc. increased its stake in shares of ChemoCentryx by 3.1% during the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 15,685 shares of the biopharmaceutical company’s stock worth $630,000 after purchasing an additional 470 shares during the period. 76.36% of the stock is owned by institutional investors.
CCXI traded down $0.57 during trading on Monday, hitting $47.55. The stock had a trading volume of 550,900 shares, compared to its average volume of 470,572. The firm has a market capitalization of $3.28 billion, a P/E ratio of -88.06 and a beta of 1.74. The company has a debt-to-equity ratio of 0.12, a quick ratio of 9.00 and a current ratio of 9.00. ChemoCentryx has a twelve month low of $6.44 and a twelve month high of $65.43. The company’s 50-day moving average price is $53.65 and its 200 day moving average price is $52.06.
About ChemoCentryx
ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy.
See Also: FTSE 100 Index
Get a free copy of the Zacks research report on ChemoCentryx (CCXI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
20 “Past Their Prime” Stocks to Dump From Your Portfolio
Did you know the S&P 500 as we know it today does not look anything close to what it looked like 30 years ago? In 1987, IBM, Exxon, GE, Shell, AT&T, Merck, Du Pont, Philip Morris, Ford and GM had the largest market caps on the S&P 500. ExxonMobil is the only company on that list to remain in the top 10 in 2017. Even just 15 years ago, companies like Radio Shack, AOL, Yahoo and Blockbuster were an important part of the S&P 500. Now, these companies no longer exist as public companies.
As the years go by, some companies lose their luster and others rise to the top of the markets. We’ve already seen this in the last few decades with tech companies surpassing industrial and energy companies that once dominated the S&P 500. It’s hard to know what the next mega trend will be that will knock Apple, Google and Amazon off the top rankings of the S&P 500, but we do know that companies won’t stay on the S&P 500 forever.
We’ve identified 20 companies that are past their prime. They aren’t at risk of a near-term delisting from the S&P 500, but they are showing negative earnings growth for the next several years. If you own any of these stocks, consider selling them now before they become the next Yahoo, Radio Shack, Blockbuster, AOL and are sold off for a fraction of their former value.
View the “20 “Past Their Prime” Stocks to Dump From Your Portfolio”.
